GSK plc
GSK- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001131399
No open-market purchases or sales by GSK plc insiders were filed in the last 90 days; 1,048 institutions reported holding it in 13F filings for Q2 2026, worth $18.2B in total; no superinvestor holds it.
Other share classesGLAXF
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +28 vs. previous quarter
- 1,048
- 13F valueReported value at the end of Q2 2026
- $18.2B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding GSK, Q2 2026
No superinvestor reported holding GSK at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by GSK plc insiders from Form 4, newest first.
No open-market purchases or sales by GSK plc insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in GSK plc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 64,961,641 | $3.41B | 0.15% | −2,700,005−4.0% | Reduced |
| Dodge & Cox | 48,197,514 | $2.53B | 1.32% | −10,465,460−17.8% | Reduced |
| Fisher Asset Management, LLC | 35,722,792 | $1.87B | 0.56% | +1,200,429+3.5% | Added |
| Primecap Management Co | 25,182,068 | $1.32B | 0.78% | −22,470−0.1% | Reduced |
| Wellington Management Group LLP | 11,396,249 | $597.4M | 0.10% | −321,364−2.7% | Reduced |
| JTC Employer Solutions Trusteee Ltd | 8,592,987 | $450.3M | 36.11% | −449,402−5.0% | Reduced |
| Morgan Stanley | 7,657,562 | $401.4M | 0.02% | −3,373,089−30.6% | Reduced |
| Royal Bank of Canada | 7,588,928 | $397.8M | 0.07% | +82,142+1.1% | Added |
| Price T Rowe Associates Inc | 6,923,642 | $362.9M | 0.04% | −399,191−5.5% | Reduced |
| Acadian Asset Management LLC | 6,660,434 | $349.1M | 0.41% | −5,136,651−43.5% | Reduced |